Published in Law and Health Weekly, January 12th, 2004
The program includes the clinical development candidate (ARRY-142886) and related intellectual property.
Under the agreement, Array will receive an upfront payment of $10 million, research funding, potential development milestones of over $85 million (dependent upon the number of successfully commercialized products), and royalties on product sales. Array plans to file an investigational new drug application (IND) and initiate a phase I clinical trial during 2004.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly